Company / Free Cash Flow
Avalo Therapeutics, Inc. Free Cash Flow History
FY2017-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$26.8M
FY2022
5-year range
-$71.0M / -$26.8M
FY2018-FY2022
Trend
+62.2%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2022 after 4 years of decline, reaching -$27M.
Based on SEC 10-K filings.
-$27M in FY2022.
Improved from -$41M to -$27M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, free cash flow increased 62.2% year-over-year.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -$26.8M | +62.2% |
| FY2021 | -$71.0M | -74.9% |
| FY2020 | -$40.6M | -109.3% |
| FY2019 | -$19.4M | -425.3% |
| FY2018 | -$3.7M | -129.4% |
| FY2017 | $12.6M | - |
As of FY2022 · SEC Form 10-K · Last checked Jun 21, 2026